Preliminary data from the dose escalation cohort will be presented at the European Society of Medical Oncology (ESMO) Gastrointestinal Cancers (GI) Congress 2025, being held July 2-5 in Barcelona ...

ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data presentations from the LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA ...

BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...

Abstract: Deep learning approaches require enough training samples to perform well, but it is a challenge to collect enough real training data and label them manually. In this letter, we propose a ...

PKP2-ACM is an inherited heart disease caused by mutations in the PKP2 gene and characterized by life-threatening ventricular arrhythmias, cardiac structural abnormalities, and sudden cardiac ...

These data position SCS drug delivery as a transformative approach and promising mainstream option in treating retinal diseases,” concluded Dr. Chong. In addition to the presentations, Viral Kansara, ...

“We are pleased to share initial safety data from the ELIMINATE-B trial for PBGENE-HBV at this year’s EASL congress. Since initiating the trial, we have made rapid progress activating global ...

Energy Transfer LP (NYSE: ET) reported solid financial results for the first quarter of 2025, with adjusted EBITDA reaching $4.10 billion, up 6% compared to the same period last year.The company ...

The data were from the Phase 2 clinical study of high-dose IBI302 (NCT05403749) to evaluate the efficacy, safety and dosing intervals in patients with nAMD over a one-year treatment period. A total of ...

George Magrath, M.D., Chief Executive Officer of Opus Genetics, added, “Presentation of the 12-month data at ARVO underscores the growing interest in this program, and if approved, OPGx-LCA5 ...

30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal The data demonstrate statistically ...

The presentation, entitled “Recovery of Cone-Mediated Vision in a Severe Ciliopathy after Gene Augmentation: One Year Results of a Phase I/II Trial for LCA5-LCA,” was delivered by Dr. Tomas Aleman of ...